Clovis Oncology Inc. (CLVS)

46.26
2.10 4.34
NASDAQ : Health Technology
Prev Close 48.36
Open 48.54
Day Low/High 46.14 / 50.19
52 Wk Low/High 45.42 / 99.45
Volume 1.58M
Avg Volume 1.31M
Exchange NASDAQ
Shares Outstanding 52.40M
Market Cap 2.63B
EPS -7.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

3 Potential Biotech Buyout Targets in the Second Quarter

3 Potential Biotech Buyout Targets in the Second Quarter

Novartis' deal for AveXis has ignited a rally in other gene-therapy concerns.

Possible Biotech Takeout Plays

Possible Biotech Takeout Plays

A look at possible second-quarter M&A activity in the biotech sector.

Infographic: Understanding Ovarian Cancer (Graphic: Business Wire)

Infographic: Understanding Ovarian Cancer (Graphic: Business Wire)

Clovis Oncology, Inc. (NASDAQ:CLVS) today announced that the U.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: GSM, RSPP, SVM, TDS Downgrades: AG, BGS, DJCO, EVC, GLRE, TCP Initiations: CLVS Read on to get TheStreet Quant Ratings' detailed report:

Clovis Oncology Initiates Early Access Program For Rucaparib As Treatment And As Maintenance Therapy In Recurrent Ovarian Cancer In Europe

Clovis Oncology Initiates Early Access Program For Rucaparib As Treatment And As Maintenance Therapy In Recurrent Ovarian Cancer In Europe

Clovis Oncology, Inc. (NASDAQ:CLVS) today announced the initiation of an early access program in Europe for rucaparib for treatment and as maintenance therapy in recurrent ovarian cancer.

CHMP Grants Positive Opinion For Clovis Oncology's Rubraca® (rucaparib) Tablets

CHMP Grants Positive Opinion For Clovis Oncology's Rubraca® (rucaparib) Tablets

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the European Union's (EU) European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the...

Which Hot Biotech Name Will Be Acquired Next?

Which Hot Biotech Name Will Be Acquired Next?

Your burning biotech questions answered in our latest mailbag.

Bret Jensen's Biotech Mailbag

Bret Jensen's Biotech Mailbag

We'll answer two of the common questions we have received so far in March.

Clovis Oncology Announces Notice Of Allowance For Rucaparib High Dosage Strength Tablet Patent With Expiration In 2035

Clovis Oncology Announces Notice Of Allowance For Rucaparib High Dosage Strength Tablet Patent With Expiration In 2035

Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that the Company has received a Notice of Allowance from the United States Patent and Trademark Office in United States Patent Application 14/828,065 with claims...

Clovis Oncology To Present At The Barclays Global Healthcare Conference

Clovis Oncology To Present At The Barclays Global Healthcare Conference

Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that Patrick J.

Clovis Oncology Announces 2017 Operating Results

Clovis Oncology Announces 2017 Operating Results

Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter and year ended December 31, 2017, and provided an update on the Company's clinical development programs and regulatory and commercial...

Clovis Oncology Receives Positive Trend Vote From CHMP In European Regulatory Review For Rucaparib Ovarian Cancer Treatment Indication

Clovis Oncology Receives Positive Trend Vote From CHMP In European Regulatory Review For Rucaparib Ovarian Cancer Treatment Indication

Clovis Oncology, Inc. (NASDAQ: CLVS) announced today an update to the ongoing regulatory review for the Marketing Authorization Application (MAA) for rucaparib tablets as monotherapy for the treatment of a limited...

Clovis Oncology To Announce Fourth Quarter And Full Year 2017 Financial Results And Host Webcast Conference Call On February 26

Clovis Oncology To Announce Fourth Quarter And Full Year 2017 Financial Results And Host Webcast Conference Call On February 26

Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its fourth quarter and full year 2017 financial results on Monday, February 26, 2018, after the close of the U.

Five Rules for This Market Beast: Cramer's 'Mad Money' Recap (Tues 1/16/18)

Five Rules for This Market Beast: Cramer's 'Mad Money' Recap (Tues 1/16/18)

Even with Monday's sharp reversal, Jim Cramer says he still likes this market.

Clovis Oncology To Present At The 36th Annual J.P. Morgan Healthcare Conference

Clovis Oncology To Present At The 36th Annual J.P. Morgan Healthcare Conference

Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its Chief Executive Officer and President, Patrick J.

Rucaparib MAA For The Ovarian Cancer Treatment Indication Referred By CHMP To Scientific Advisory Group On Oncology For Review Expected In February 2018

Rucaparib MAA For The Ovarian Cancer Treatment Indication Referred By CHMP To Scientific Advisory Group On Oncology For Review Expected In February 2018

Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that the European Union's (EU) European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has requested that the Scientific Advisory Group...

Clovis Up on Priority Review Status for Ovarian Cancer Therapy -- Biotech Mover

Clovis Up on Priority Review Status for Ovarian Cancer Therapy -- Biotech Mover

The FDA has accepted the Boulder, Colo.-based firm's supplemental New Drug Application for ovarian cancer therapy rucaparib and granted priority review status to the application.

Clovis Announces Priority Review Designation For Rucaparib Supplemental New Drug Application

Clovis Announces Priority Review Designation For Rucaparib Supplemental New Drug Application

Clovis Oncology (NASDAQ: CLVS) announced today that the U.S.

Clovis Oncology To Present At The Stifel 2017 Healthcare Conference

Clovis Oncology To Present At The Stifel 2017 Healthcare Conference

Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its Chief Executive Officer and President, Patrick J.

Notable Thursday Option Activity: CLVS, GOGO, ENDP

Notable Thursday Option Activity: CLVS, GOGO, ENDP

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Clovis Oncology Inc , where a total of 5,548 contracts have traded so far, representing approximately 554,800 underlying shares. That amounts to about 47.9% of CLVS's average daily trading volume over the past month of 1.2 million shares.

Clovis Oncology Announces Third Quarter 2017 Operating Results

Clovis Oncology Announces Third Quarter 2017 Operating Results

Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended September 30, 2017, and provided an update on the Company's clinical development programs and regulatory outlook for the remainder...

Clovis Oncology To Announce Third Quarter 2017 Financial Results And Host Webcast Conference Call On November 1

Clovis Oncology To Announce Third Quarter 2017 Financial Results And Host Webcast Conference Call On November 1

Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its third quarter 2017 financial results on Wednesday, November 1, 2017, after the close of the U.

What's Hot and What's Not: Cramer's 'Mad Money' Recap (Thursday 10/12/17)

What's Hot and What's Not: Cramer's 'Mad Money' Recap (Thursday 10/12/17)

In this sometimes fickle market, supply and demand are still at play.

Clovis Oncology Submits Supplemental New Drug Application For Rucaparib As Maintenance Treatment For Patients With Platinum-Sensitive Recurrent Ovarian Cancer

Clovis Oncology Submits Supplemental New Drug Application For Rucaparib As Maintenance Treatment For Patients With Platinum-Sensitive Recurrent Ovarian Cancer

Clovis Oncology (NASDAQ: CLVS) announced today that the company has submitted a supplemental New Drug Application (sNDA) to the U.

Clovis Oncology's Rucaparib ARIEL3 Study Data Published In The Lancet

Clovis Oncology's Rucaparib ARIEL3 Study Data Published In The Lancet

Clovis Oncology, Inc. (NASDAQ: CLVS) announced that comprehensive data from the Phase 3 ARIEL3 study of rucaparib for maintenance treatment of advanced ovarian cancer were published online today in The Lancet.

Clovis Spikes on Phase 3 Data for Ovarian Cancer Drug- Biotech Movers

Clovis Spikes on Phase 3 Data for Ovarian Cancer Drug- Biotech Movers

The company is scheduled Friday afternoon to present comprehensive data from its Phase 3 study of rucaparib at the European Society for Medical Oncology Congress in Madrid.

Clovis Oncology Presents Comprehensive Dataset From Successful Phase 3 ARIEL3 Maintenance Treatment Trial Of Rucaparib In Advanced Ovarian Cancer At ESMO 2017

Clovis Oncology Presents Comprehensive Dataset From Successful Phase 3 ARIEL3 Maintenance Treatment Trial Of Rucaparib In Advanced Ovarian Cancer At ESMO 2017

Clovis Oncology, Inc. (NASDAQ: CLVS) announced the first presentation of a comprehensive dataset from its Phase 3 ARIEL3 study of rucaparib at the 2017 European Society for Medical Oncology (ESMO) Congress taking place in...

Juno, bluebird In Focus as Targets Following Gilead-Kite Aquisition

Juno, bluebird In Focus as Targets Following Gilead-Kite Aquisition

More Immunotherapy Buyouts Likely After Kite Sale

TheStreet Quant Rating: D- (Sell)